Farampator

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Farampator
Farampator.svg
Farampator ball-and-stick model.png
Legal status
Legal status
Identifiers
Synonyms CX-691, Org 24448
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
Formula C12H13N3O2
Molar mass 231.25052 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Farampator (CX-691, Org 24448) is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator has been transferred, and development is continuing.

Farampator has been investigated for its effect on AMPA receptors and researched for potential use in the treatment of schizophrenia and Alzheimer's Disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects (SEs) such as headache, somnolence and nausea. Subjects with SEs had significantly higher plasma levels of farampator than subjects without SEs. Additional analyses revealed that in the farampator condition the group without SEs showed a significantly superior memory performance relative to the group with SEs. [1]

References[edit]

  1. ^ Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology. 2007 Jun;32(6):1272-83. doi:10.1038/sj.npp.1301257 PMID 17119538